IceCure H1 2026 Revenue Up 45% to $1.8M; Cash $12.0M
IceCure Medical reported a 45% year-over-year revenue increase to $1.8 million for the first half of 2026, driven by growth in both systems and disposable probes. Despite the revenue growth, the company posted a net loss of $8.775 million and ended the period with $12.0 million in cash and cash equivalents, bolstered by $8.5 million in gross proceeds from recent financings. The company acknowledged substantial doubts about its ability to continue as a going concern and is currently in mediation for a class action lawsuit seeking approximately $133.6 million in damages.
Key Highlights
- Revenue increased 45% year-over-year to $1.8 million for the first half of 2026.
- Net loss for H1 2026 was $8.775 million, compared to $6.952 million for H1 2025.
- Cash and cash equivalents stood at $12.0 million as of June 30, 2026, up from $8.9 million at year-end 2025.
- Expanded U.S. commercial footprint with approximately 70% growth in its active installed base.
- Raised approximately $8.5 million in gross proceeds from multiple financings during H1 2026.
- Company faces substantial doubts about its ability to continue as a going concern due to accumulated losses and negative cash flows.
- A class action lawsuit seeking approximately $133.6 million in damages is currently in mediation.
- Effected a 1-for-30 reverse stock split on June 4, 2026.
Price Impact
More from ICCM
IceCure Medical Announces Annual and Special General Meeting on Nov 2, 2026
IceCure Medical Discloses David Salton's Professional Background
IceCure Medical to Vote on Warrant Amendments, Exercise Price Cut to $3.00